WEF26: ‘Human Capital Is the Key Driver of Economic Competitiveness’ January 21, 2026 For economies to remain competitive in the future, they must prioritize investments in human capital, Her Royal Highness Princess Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, told the World Economic Forum (WEF) Annual Meeting 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120585206/en/ [...]
Finovate Announces Live Demo Companies and Industry-Leading Speakers for FinovateEurope 2026 January 21, 2026 Finovate, a research and events firm focused on innovation in financial and banking technology, today announced its list of demo companies and featured speakers for FinovateEurope 2026, taking place February 10-11 at the Intercontinental O2 in London. A premier event dedicated to shaping the digital future of the financial services industry, FinovateEurope is set to [...]
Oshkosh Defense to Showcase Combat-Proven JLTV at International Armoured Vehicles Conference January 19, 2026 Only OEM offering fully fielded JLTV directly to allied nations through Direct Commercial Sales; Strengthens UK and European partnerships through collaborative modernization
Industry Leaders Unite to Create First-Ever End-to-End Critical Connectivity Ecosystem Showcase at ISE Barcelona 2026 January 16, 2026 Alfalite, Brainstorm, Dejero, Domo Broadcast Systems, FOR-A, KitPlus, Ontario Soluciones and RGB Spectrum partner to demonstrate revolutionary integrated solution "Where Critical Moments Meet Unbreakable Connections"
Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference January 16, 2026 Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies* and 3 additional studies to be initiated in 2026. Almirall’s sustained trajectory of growth and profitability enables the company to reach more patients and supports a growth outlook of double-digit net sales through 2030, combined biologics peak sales of approximately €800 MM (Ebglyss® and Ilumetri®), and a 25% EBITDA margin by 2028. Almirall's leadership in medical dermatology, biologics growth, and continued strong performance of its broad product portfolio fuel advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need.
The Delivery Conference 2026 Announces Agenda, Key Speakers, and Closing Keynote Richard Ayoade January 16, 2026 TDC 2026 unites global leaders to shape the future of AI-powered delivery Keynote insights from Mary Portas, Arka Dhar, Richard Lim, Richard Ayoade, and others Closing-party performance from British music and West End star, Alexandra Burke
Kolibri Global Energy Inc. Provides Operations Update January 16, 2026 Kolibri Global Energy Inc. (the “Company” or “Kolibri”) (TSX: KEI, NASDAQ: KGEI) is pleased to provide an operations update on its latest wells in its Tishomingo field in Oklahoma. BARNES WELLS The Barnes 6-31-2H and Barnes 6-4H wells (both 100% working interest) have been on production for approximately 30 days. The 1.5 mile lateral Barnes [...]
SOLUM to Unveil Future Vision for Smart Retail at NRF 2026: ‘Empowering Offline Stores through Data Synergy’ January 9, 2026 - 'Retail in Sync': Realizing 'Store Intelligence' by converging data beyond simple device connectivity - Introduces 'SSP' (SOLUM Store Platform): Setting the standard for digital transformation (DX) in physical retail - Four immersive Experience Zones to showcase 45 years of technological heritage and global partnership expansion
Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference January 6, 2026 Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST. 44th Annual J.P. Morgan Healthcare [...]
Iksuda to Present Preliminary Analysis of Oesophageal Cancer Data From Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium January 6, 2026 Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy that included a trastuzumab component in at least one prior treatment